Purchase by Eric Weisblum of 200 shares of Silo Pharma
| SILO Stock | USD 0.86 0.05 5.49% |
About 62% of Silo Pharma's investor base is looking to short. The analysis of current outlook of investing in Silo Pharma suggests that many traders are alarmed regarding Silo Pharma's prospects. Silo Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Silo Pharma. Many technical investors use Silo Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Silo |
Filed transaction by Silo Pharma Inc director. General open market or private purchase of non-derivative or derivative security
Read at macroaxis.com
Silo Pharma Fundamental Analysis
We analyze Silo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Silo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Silo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Silo Pharma is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Silo Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Silo Pharma otc stock to make a market-neutral strategy. Peer analysis of Silo Pharma could also be used in its relative valuation, which is a method of valuing Silo Pharma by comparing valuation metrics with similar companies.
Peers
Silo Pharma Related Equities
| BCDA | Biocardia | 4.87 | ||||
| URGN | UroGen Pharma | 4.79 | ||||
| INDP | Indaptus Therapeutics | 3.00 | ||||
| IVA | Inventiva | 1.91 | ||||
| TPST | Tempest Therapeutics | 1.10 | ||||
| FBRX | Forte Biosciences | 0.50 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| RZLT | Rezolute | 1.02 | ||||
| SBMFF | Sino Biopharmaceutica | 2.33 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.11 |
Other Information on Investing in Silo OTC Stock
Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.